PMA supplement
P040044 S113: Cordis Mynx Vascular Closure Portfolio (VCP): MynxGrip, Mynx Control, and Mynx Control Venous Vascular Closure
FDA PMA supplement · Special (Immediate Track) · Cordis US Corporation
Key facts
| Original PMA | P040044 |
|---|---|
| Supplement number | S113 |
| Supplement type | Special (Immediate Track) |
| Reason for the supplement | Labeling Change - Indications/instructions/shelf life/tradename |
| Trade name | Cordis Mynx Vascular Closure Portfolio (VCP): MynxGrip, Mynx Control, and Mynx Control Venous Vascular Closure |
| Generic name | Device, hemostasis, vascular |
| Applicant | Cordis US Corporation |
| Product code | MGB |
| Received date | Apr 14, 2026 |
| Decision date | May 14, 2026 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: